Overview: HHV-8 IgM TestIntroduction: The HHV-8 IgM Test tests for HHV-8 IgM antibodies to diagnose recent infection with human herpesvirus 8, linked to Kaposi's sarcoma, aiding in early diagnosis. Affecting 1 in 10,000 people in endemic areas, HHV-8 poses diagnostic challenges due to rapid progression. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high sensitivity, supporting virology screening. This test is vital for diagnosis, early intervention, and improving outcomes in oncology.
Other Names: HHV-8 IgM Antibody Test, Recent Infection Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: HHV-8 serology began in the 1990s with research by Chang, who identified the virus. ELISA advancements in the 2000s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects HHV-8 IgM antibodies to diagnose recent infection, guides early therapy, and evaluates patients with recent symptoms, aiming to prevent disease.
Test Parameters: HHV-8 IgM antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of recent symptoms.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document skin lesions or recent symptoms. Include current medications or immune status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., sarcoma), and sample collection risks.
Procedural Considerations: Uses ELISA to measure IgM, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive IgM confirms recent infection, guiding therapy. Early intervention might prevent progression, while untreated cases lead to cancer. Normal levels may require PCR.
Specialist Consultation: Consult an oncologist or infectious disease specialist for interpretation.
Additional Supporting Tests: HHV-8 PCR, biopsy, or imaging to confirm diagnosis.
Test Limitations: Indicates recent infection only; correlation with symptoms needed. False positives possible with cross-reactivity.
References: CDC Guidelines, 2023; New England Journal of Medicine, Chang Y, 2022.
